83 related articles for article (PubMed ID: 6111334)
1. The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs.
Knox JM; Orr MW; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):261-3. PubMed ID: 6111334
[TBL] [Abstract][Full Text] [Related]
2. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.
Orr MW; Knox JM; Allen R; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1981 Mar; 11(3):255-9. PubMed ID: 6111333
[TBL] [Abstract][Full Text] [Related]
3. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.
Boullin DJ; Woods HF; Grimes RP; Grahame-Smith DG
Br J Clin Pharmacol; 1975 Feb; 2(1):29-35. PubMed ID: 791316
[TBL] [Abstract][Full Text] [Related]
4. Platelet aggregation response in schizophrenia and prostaglandin E1.
Kaiya H; Imai H; Muramatsu Y; Nozaki M; Fujimura H; Adachi S; Namba M
Psychiatry Res; 1983 Aug; 9(4):309-18. PubMed ID: 6139836
[TBL] [Abstract][Full Text] [Related]
5. Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics.
Dinan TG
Psychol Med; 1987 Nov; 17(4):875-81. PubMed ID: 2893407
[TBL] [Abstract][Full Text] [Related]
6. Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine.
Boullin DJ; Orr MW
Br J Clin Pharmacol; 1976 Oct; 3(5):929-33. PubMed ID: 973989
[TBL] [Abstract][Full Text] [Related]
7. The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation.
Dietrich-Muszalska A; Rabe-Jablonska J; Nowak P; Kontek B
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):268-75. PubMed ID: 20218792
[TBL] [Abstract][Full Text] [Related]
8. Changes in platelet aggregatory responses to collagen and 5-hydroxytryptamine in depressed, schizophrenic and manic patients.
McAdams C; Leonard BE
Int Clin Psychopharmacol; 1992 Nov; 7(2):81-5. PubMed ID: 1487625
[TBL] [Abstract][Full Text] [Related]
9. Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients.
Meltzer HY; Duncavage MB; Jackman H; Arora RC; Tricou BJ; Young M
Am J Psychiatry; 1982 Oct; 139(10):1242-8. PubMed ID: 6127035
[TBL] [Abstract][Full Text] [Related]
10. The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro.
Dietrich-Muszalska A; Rabe-Jabłońska J; Olas B
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):293-9. PubMed ID: 19675971
[TBL] [Abstract][Full Text] [Related]
11. Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties.
Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
Br J Clin Pharmacol; 1975 Feb; 2(1):37-9. PubMed ID: 791317
[TBL] [Abstract][Full Text] [Related]
12. Increased platelet aggregation in patients receiving chlorpromazine: responses to 5-hydroxytryptamine, dopamine and N-dimethyl dopamine.
Boullin DJ; Grimes RP
Br J Clin Pharmacol; 1976 Aug; 3(4):649-53. PubMed ID: 22216508
[TBL] [Abstract][Full Text] [Related]
13. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia.
Yao JK; van Kammen DP; Moss HB; Sokulski DE
Psychiatry Res; 1996 Jul; 63(2-3):123-32. PubMed ID: 8878308
[TBL] [Abstract][Full Text] [Related]
14. The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.
Orr MW; Boullin DJ
Br J Clin Pharmacol; 1976 Oct; 3(5):925-8. PubMed ID: 973988
[TBL] [Abstract][Full Text] [Related]
15. Platelet aggregation and chlorpromazine therapy.
Boullin DJ; Know JM; Peters JR; Orr MW; Gelder MG; Grahame-Smith DG
Br J Clin Pharmacol; 1978 Dec; 6(6):538-40. PubMed ID: 728326
[No Abstract] [Full Text] [Related]
16. Serotonin receptor site in human platelets from control and chlorpromazine treated subjects.
Oppenheim B; Hefez A; Youdim MB
Prog Biochem Pharmacol; 1980; 16():119-32. PubMed ID: 7443729
[TBL] [Abstract][Full Text] [Related]
17. Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
Youdim MB; Hefez A; Oppenheim B
Br J Clin Pharmacol; 1981 Oct; 12(4):535-42. PubMed ID: 7295487
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
[No Abstract] [Full Text] [Related]
19. Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment.
Schächter M; Geaney DP; Grahame-Smith DG; Cowen PJ; Elliott JM
Br J Clin Pharmacol; 1985 Apr; 19(4):453-7. PubMed ID: 2859873
[TBL] [Abstract][Full Text] [Related]
20. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.
Michal F; Motamed M
Br J Pharmacol; 1976 Feb; 56(2):209-18. PubMed ID: 1252669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
